Conventional fetal ultrasonography necessitates highly trained operators to manually acquire anatomical images and Doppler flow measurements at specific instances during pregnancy. These “snapshot” assessments, although clinically valuable, are constrained by their intermittent nature and dependency on healthcare facility access. The UPatch addresses these challenges by integrating sophisticated ultrasound transducer arrays into a flexible, skin-conforming patch that can be comfortably worn on the maternal abdomen. This design allows for ongoing acquisition of key fetal parameters, including detailed anatomical structures and blood flow velocities, without active clinician involvement.

A pivotal breakthrough underpinning the UPatch’s functionality is its embedded real-time image segmentation system powered by advanced machine learning algorithms. This enables autonomous identification and tracking of target fetal and maternal blood vessels throughout the monitoring period. As a result, the device can acquire continuous Doppler blood flow spectra, maintaining data integrity even amidst fetal and maternal movements, which traditionally hindered reliable measurement acquisition. The synergy between hardware innovation and intelligent software thus facilitates stable, high-fidelity fetal monitoring outside clinical environments.

Validation studies encompassing 62 pregnancies have demonstrated that the UPatch yields anatomical and hemodynamic measurements in very close agreement with those obtained by conventional handheld clinical ultrasound devices. This concordance underscores the patch’s potential to match clinical-grade imaging standards while offering the added benefits of continuous monitoring. Importantly, the autonomous operation reduces the need for sonographer intervention, potentially democratizing access to essential prenatal diagnostics, especially in resource-limited settings.

Insights gleaned from continuous monitoring data of 52 pregnant women reveal compelling correlations with diverse stratified perinatal conditions. The UPatch successfully differentiated between normal pregnancies and those complicated by factors such as small for gestational age (SGA), large for gestational age (LGA), gestational diabetes, preeclampsia, and gestational hypertension. These findings suggest the device’s capability to provide early warnings of fetal compromise, offering clinicians a dynamic overview of placental function and fetal well-being that was previously unattainable through sporadic clinical ultrasounds.

The ability to track fetal hemodynamic responses in real time is especially consequential in managing high-risk pregnancies where fetal growth abnormalities or hypertensive disorders could induce acute complications. Continuous Doppler assessment of critical vessels such as the umbilical artery or middle cerebral artery provides nuanced hemodynamic profiles, enabling clinicians to detect subtle deviations from normative patterns. This proactive surveillance could inform timely interventions, ultimately improving perinatal outcomes.

A further stride towards real-world applicability lies in the UPatch’s comfort and form factor. Its flexible design ensures adherence to the maternal abdomen without compromising mobility or daily activities. Unlike bulkier ultrasound equipment, this patch-based system offers unprecedented patient convenience, facilitating long-term monitoring at home, thus reducing hospital visits and healthcare system burdens. Such attributes render it ideally suited for continuous outpatient fetal surveillance.

Anticipating future integration, the research team envisions coupling the UPatch with miniaturized electronic circuits and fully wireless operation modules. This would enable seamless data transmission to cloud platforms for remote analysis by healthcare providers, empowering prenatal telemedicine paradigms. The miniaturization roadmap also anticipates enhanced battery life and user-friendly interfaces that could further ease adoption by expectant mothers and clinicians alike.

Technically, the device employs advanced piezoelectric materials arranged in dense transducer arrays capable of both B-mode anatomical imaging and pulsed-wave Doppler flow measurements. The flexible substrate conforms intimately to the skin surface, minimizing acoustic impedance mismatches and motion artifacts. These engineering innovations are complemented by embedded signal processing units capable of handling high-throughput ultrasound data streams in real time.

Moreover, sophisticated deep learning frameworks embedded within the patch facilitate segmentation and vessel tracking without operator input. The algorithms were trained on diverse ultrasound datasets to enhance robustness across variable fetal positions, gestational ages, and maternal body habitus. This autonomous image analysis pipeline distinguishes vessels of interest while compensating for maternal respiratory and fetal movements, critical for consistent spectral Doppler acquisition.

From a clinical workflow perspective, the UPatch holds transformative potentials. By offering continuous longitudinal datasets, clinicians can access detailed growth trajectories and vascular flow patterns over days or weeks. This contrasts starkly with current discrete evaluations, where critical temporal dynamics might be missed. The enhanced temporal resolution will enrich diagnostic accuracy and may guide personalized management strategies tailored to the evolving fetal condition.

The UPatch’s data-rich outputs also present an opportunity for integration with other prenatal biometrics and electronic health records, enabling multifactorial risk stratification. Machine learning models synthesizing diverse clinical inputs alongside continuous ultrasound monitoring could generate predictive analytics, assisting early detection of fetal compromise and informing obstetric decision-making. This heralds a new paradigm of data-driven personalized prenatal care.

Importantly, this technology could address global disparities in prenatal healthcare, where limited access to skilled sonographers and diagnostic tools often results in delayed or inadequate fetal assessment. The ease of use and autonomous operation of the UPatch could enhance monitoring accessibility in underserved settings, potentially reducing adverse outcomes associated with undetected fetal distress.

While promising, the UPatch still requires further optimization, especially in expanding the wireless capabilities and integrating the full electronic system into a compact wearable unit. Clinical trials involving larger cohorts and diverse populations will be essential to robustly evaluate its efficacy across varying clinical conditions and gestational stages. Regulatory approvals and standardization will also be integral to its widescale adoption.

Nevertheless, the emergence of the UPatch marks a significant milestone in prenatal diagnostics, underscoring the synergy between material innovation, machine learning, and clinical medicine. By enabling continuous, autonomous fetal monitoring through a wearable platform, this technology opens new frontiers in maternal-fetal care, with the potential to improve outcomes for countless pregnancies worldwide. As development continues, the vision of seamless, at-home fetal surveillance is steadily turning into reality.

In conclusion, the wearable ultrasound patch not only redefines fetal monitoring by allowing uninterrupted, hands-free acquisition of critical biometric data but also establishes a new standard for accessible, data-driven prenatal care. By bridging gaps in traditional ultrasound limitations, it equips clinicians with richer insights and expectant mothers with enhanced peace of mind. The future of fetal health monitoring is on the horizon, glowing with possibility and powered by innovation.

Subject of Research: Fetal monitoring and prenatal care using wearable ultrasound technology.

Article Title: Fetal monitoring for high-risk pregnancies using a wearable ultrasound patch.

Article References:
Park, G., Bian, Y., Huang, H. et al. Fetal monitoring for high-risk pregnancies using a wearable ultrasound patch. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03140-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41587-026-03140-1

Preeclampsia, characterized by dangerously high blood pressure and organ damage during pregnancy, remains a leading cause of maternal and neonatal morbidity and mortality worldwide. Traditional screening methods in the first trimester primarily rely on maternal risk factors and placental biomarkers, which unfortunately fail to identify over 50% of at-risk pregnancies before the disease’s clinical manifestation. Recognizing this diagnostic gap, the collaborative research initiative spearheaded by the Carlos Simón Foundation and iPremom set out to harness advanced genomics and machine learning for more sensitive, timely detection.

The study enrolled an unprecedented cohort of 9,586 pregnant women across 14 major Spanish hospitals between September 2021 and June 2024. Out of these, a nested case-control subset of 216 participants was meticulously selected for intensive molecular profiling. Researchers collected multiple plasma samples at critical gestational windows—specifically between 9 and 14 weeks, 18 to 28 weeks, and beyond 28 weeks or at diagnosis—to assay circulating cfRNA molecules which serve as dynamic indicators of gene expression changes in maternal and placental tissues.

Employing cutting-edge next-generation sequencing on 548 plasma samples using Illumina technology, the team decoded complex cfRNA profiles. These molecular signatures were then analyzed through sophisticated machine learning algorithms to develop predictive models capable of discerning pregnancies at risk for both early-onset (EOPE) and late-onset preeclampsia (LOPE), well in advance of symptomatic detection.

Remarkably, the first-trimester cfRNA model flagged EOPE with 83% sensitivity and 90% specificity, boasting an average area under the curve (AUC) of 0.88. This implies that on average, the test predicted EOPE approximately 18 weeks—nearly five months—prior to clinical diagnosis. Such temporal advantage presents a compelling opportunity to commence preventative therapies and heightened surveillance protocols, potentially averting severe complications for both mother and child.

Molecular investigation into the predictive transcripts revealed close links to genes involved in maternal endometrial function, particularly those associated with decidualisation resistance. Decidualisation refers to the vital transformation of the uterine lining facilitating embryo implantation and placental development, and its impairment is increasingly implicated in EOPE pathogenesis. Nearly half of the identified cfRNA transcripts corresponded to these uterine remodeling pathways, underscoring a key mechanistic role of uterine dysfunction.

In contrast, cfRNA signatures predictive of LOPE emerged as distinct, with minimal overlap in decidualisation-related transcripts. Instead, late-onset preeclampsia exhibited systemic biological signatures involving immune response and hepatic pathways, emphasizing a more localized and temporally delayed pathophysiology. On average, LOPE was predicted roughly 14.9 weeks before symptom onset, allowing a critical window for early detection despite its complex biological roots.

Dr. Nerea Castillo Marco, the study’s lead author, emphasized the novelty of this approach in prenatal medicine: “Our findings demonstrate for the first time that a routine maternal blood draw during early pregnancy can deliver highly accurate forecasts of preeclampsia, creating an invaluable window for intervention before clinical manifestations.” The precision and non-invasiveness of cfRNA liquid biopsy herald a paradigm shift in maternal-fetal medicine, particularly for a condition historically challenging to diagnose preemptively.

Beyond the predictive capabilities, the transcriptomic landscape mapped in this study provides unprecedented molecular insights into the diverse organ systems impacted during EOPE, including liver, kidney, brain, lungs, and placenta. This multisystem involvement confirms that EOPE encompasses widespread systemic dysregulation rather than isolated placental pathology. Conversely, LOPE’s molecular footprint concentrated on immune and liver-related processes further delineates the two forms as distinct clinical and biological entities.

Project leader Dr. Tamara Garrido highlighted the immediate translational potential: “With ongoing prospective clinical validation underway, we anticipate that cfRNA-based screening will soon integrate seamlessly into routine prenatal care, providing obstetricians worldwide with a robust tool to identify high-risk pregnancies proactively.” Regulatory reviews and clinical deployment efforts are progressing rapidly, with potential availability of this revolutionary screening method expected within the next year.

The implications of this study extend far beyond diagnostics. By elucidating molecular pathways implicated in preeclampsia development, it paves the way for targeted therapeutic research and personalized medicine approaches, aiming to improve maternal and neonatal outcomes on a global scale. This aligns closely with broader public health goals to reduce preventable pregnancy complications and enhance reproductive healthcare equity.

Commenting on these seminal findings, Prof. Dr. Karen Sermon, Chair of ESHRE, stated, “This research not only marks a formidable advance in prenatal disease prevention but also deepens our molecular understanding of preeclampsia—a complex and often enigmatic pregnancy disorder—thus fostering future innovation both in science and clinical practice.”

The study abstract is set to be published imminently in Human Reproduction, one of the world’s foremost journals dedicated to reproductive biology and medicine. This milestone discovery underscores the power of integrating omics technologies with clinical obstetrics, heralding an era where early molecular diagnostics will become central to safeguarding maternal and fetal health worldwide.

Subject of Research: Early detection of preeclampsia using cell-free RNA liquid biopsy in maternal plasma during the first trimester.

Article Title: (Not provided)

News Publication Date: Monday, 30 June 2025

References:
[1] Castillo Marco, N., et al. (2025) Maternal plasma cell-free RNA as a liquid biopsy for first-trimester screening of early and late-onset preeclampsia. Nature Communications (Under review) [preprint] & Human Reproduction (abstract forthcoming)
[2] World Health Organization. (2025). Pre-eclampsia – Fact Sheet.
[3] Muñoz-Blat, R., Pérez-Moraga, R., Castillo Marco, N., et al. (2025). Multi-omics-based mapping of decidualisation resistance in patients with a history of severe preeclampsia. Nature Medicine.

Keywords: Human reproduction, Pregnancy, Preeclampsia, Cell-free RNA, Liquid biopsy, First-trimester screening, Prenatal diagnostics, Maternal plasma, Decidualisation resistance, Obstetrics, Molecular biomarkers, Machine learning